[HTML][HTML] Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
Activating mutation of BRAF is a common finding in pediatric gliomas. As many as 14% of
high grade and up to 66% of certain subtypes of low grade pediatric glioma have the BRAF …
high grade and up to 66% of certain subtypes of low grade pediatric glioma have the BRAF …
Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?
M Capogiri, AJ De Micheli, A Lassaletta… - Frontiers in …, 2023 - frontiersin.org
BRAFV600E represents the most common BRAF mutation in all human cancers. Among
central nervous system (CNS) tumors, BRAFV600E is mostly found in pediatric low-grade …
central nervous system (CNS) tumors, BRAFV600E is mostly found in pediatric low-grade …
Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
V Di Nunno, L Gatto, A Tosoni, S Bartolini… - Frontiers in …, 2023 - frontiersin.org
Gliomas are molecularly heterogeneous brain tumors responsible for the most years of life
lost by any cancer. High-grade gliomas have a poor prognosis and despite multimodal …
lost by any cancer. High-grade gliomas have a poor prognosis and despite multimodal …
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
LJ Andrews, ZA Thornton, SS Saincher, IY Yao… - Neuro …, 2022 - academic.oup.com
Background Detailed prevalence estimates of BRAFV 600 mutations and BRAF inhibitor
(BRAFi) treatment responses in V600-mutant glioma will inform trial development. Methods …
(BRAFi) treatment responses in V600-mutant glioma will inform trial development. Methods …
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
BRAF mutations are a significant driver of disease in pediatric low-grade glioma, but the
implications of BRAF alterations on the clinical course and treatment response in adult …
implications of BRAF alterations on the clinical course and treatment response in adult …
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
MJ Fusco, Y Piña, RJ Macaulay, S Sahebjam… - Cancer …, 2021 - journals.sagepub.com
Introduction BRAF V600 E mutations have been identified in a subset of patients with
primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase …
primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase …
Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition
PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor
outcomes with current chemoradiotherapy strategies. Our aim was to study the role of …
outcomes with current chemoradiotherapy strategies. Our aim was to study the role of …
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
MJ Lim-Fat, KW Song, JB Iorgulescu… - Journal of neuro …, 2021 - Springer
Purpose Although uncommon, detection of BRAF V600E mutations in adult patients with
glioblastoma has become increasingly relevant given the widespread application of …
glioblastoma has become increasingly relevant given the widespread application of …
BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets
TP Muniz, WP Mason - CNS drugs, 2023 - Springer
Gliomas are a heterogeneous group of brain tumors with limited therapeutic options.
However, identification of BRAF V600E mutations in a subset of gliomas has provided a …
However, identification of BRAF V600E mutations in a subset of gliomas has provided a …
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Purpose BRAF V600 mutations are frequently found in several glioma subtypes, including
pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in …
pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in …